Photobiomodulation for melasma treatment: Integrative review and state of the art
Photodermatology, Photoimmunology & Photomedicine · 2024
DOI: 10.1111/phpp.12935 ↗At a glance
Übersichtsarbeit in Photodermatology, Photoimmunology & Photomedicine, 2024. Written by Thais Rodrigues Galache and 3 co-authors. Institution: Postgraduate Program in Biophotonics Medicine, Universidade Nove de Julho, UNINOVE, São Paulo, SP, Brazil. Major MEDLINE topics: Low-Level Light Therapy, Melanosis, Hyperpigmentation. Cited 22 times so far (Crossref); 85 references. Funded by: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (original language)
Purpose
Photobiomodulation therapy (PBM) is a versatile technique for treating skin diseases. Melasma, a chronic hyperpigmentation condition, has recently been associated with vascular features and dermal photoaging and poses significant management challenges. We review the recent literature on melasma etiology and the evidence supporting PBM as a therapeutic modality for melasma treatment.
Methods
We conducted a comprehensive literature search in three different databases from May to August 2023, focusing on studies published in the past 10 years. The inclusion criteria comprised full‐text studies investigating low‐power lasers and/or light‐emitting diodes (LEDs) in in vitro or in vivo models, as well as clinical trials. We excluded studies discussing alternative melasma therapies or lacking experimental data. We identified additional studies by searching the reference lists of the selected articles.
Results
We identified nine relevant studies. Clinical studies, in agreement with in vitro experiments and animal models, suggest that PBM effectively reduces melasma‐associated hyperpigmentation. Specific wavelengths (red: 630 nm; amber: 585 and 590 nm; infrared: 830 and 850 nm) at radiant exposures between 1 and 20 J/cm 2 exert modulatory effects on tyrosinase activity, gene expression, and protein synthesis of melanocytic pathway components, and thus significantly reduce the melanin content. Additionally, PBM is effective in improving the dermal structure and reducing erythema and neovascularization, features recently identified as pathological components of melasma.
Conclusion
PBM emerges as a promising, contemporary, and non‐invasive procedure for treating melasma. Beyond its role in inhibiting melanogenesis, PBM shows potential in reducing erythema and vascularization and improving dermal conditions. However, robust and well‐designed clinical trials are needed to determine optimal light parameters and to evaluate the effects of PBM on melasma thoroughly.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Postgraduate Program in Biophotonics Medicine, Universidade Nove de Julho, UNINOVE, São Paulo, SP, Brazil.
- Centro Universitário Univates - CCBS, Lajeado, RS, Brazil.
ORCID profiles: Thais Rodrigues Galache, Michelle Mota Sena, João Alberto Fioravante Tassinary, Christiane Pavani
Funding
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Cite
APA
Galache, T. R., Sena, M. M., Tassinary, J. A. F., & Pavani, C. (2024). Photobiomodulation for melasma treatment: Integrative review and state of the art. Photodermatology, Photoimmunology & Photomedicine. https://doi.org/10.1111/phpp.12935
Vancouver
Galache TR, Sena MM, Tassinary JAF, Pavani C. Photobiomodulation for melasma treatment: Integrative review and state of the art. Photodermatology, Photoimmunology & Photomedicine. 2024. doi:10.1111/phpp.12935
BibTeX
@article{Galache2024,
author = {Galache, Thais Rodrigues and Sena, Michelle Mota and Tassinary, João Alberto Fioravante and Pavani, Christiane},
title = {Photobiomodulation for melasma treatment: Integrative review and state of the art},
journal = {Photodermatology, Photoimmunology & Photomedicine},
year = {2024},
doi = {10.1111/phpp.12935}
}
EUVIMED